Short answer

Two servings of fatty marine fish per week reduce cardiovascular mortality – large cohort studies and trials in populations with low baseline fish intake confirm this. Over-the-counter fish oil capsules at the same or higher doses do not reduce cardiovascular mortality in healthy adults – Cochrane 2020 (162,000 participants), VITAL 2019, and OMEMI 2021 all show null results. High-dose pharmaceutical forms work only in narrow clinical groups and carry a real side effect: atrial fibrillation.

Why this is a conversation worth having

On pharmacy shelves, fish oil sits next to vitamin D and is treated as a "safe" contribution to heart health. Supplement marketing rests on old observational data: people who eat fish have fewer heart attacks. This is true. It does not follow that a concentrated extract in a capsule produces the same effect. Over the last twenty years this hypothesis has been tested in dozens of large RCTs. The result is inconsistent and, in the general case, negative.

Dietary fish: what the studies show

The first serious data came from observational cohorts in the second half of the last century. GISSI-Prevenzione (Lancet 1999, 11,324 post-MI patients) compared omega-3 ethyl esters 1 g daily to control and showed reduced all-cause mortality and sudden cardiac death. This RCT was long cited as the basis for capsule therapy, but later analysis revealed control-group participants also shifted to a Mediterranean-style diet, so the effect likely reflected lifestyle, not the capsule.

The next layer of evidence is the Mozaffarian & Rimm cohort meta-analysis (JAMA 2006). Aggregating data on hundreds of thousands of participants, the authors showed fatty fish intake 1–2 times a week is associated with a 36 % reduction in cardiovascular mortality compared to near-zero intake. The effect is not linear – going beyond 2 servings adds no extra benefit.

The 2018 AHA Science Advisory on seafood codified this into a recommendation: 2 servings of fatty fish per week (salmon, mackerel, sardines, herring) – the baseline primary prevention strategy. ESC 2021 endorses this.

Observational cohorts do not prove causation in the strict sense. People who regularly eat fish tend to live in Mediterranean cultures, eat more balanced diets, exercise more, and smoke less. Even after adjustment for these factors, the fish signal persists – and it remains the only robust signal in the entire omega-3 / CVD literature.

Capsules in the general population: Cochrane closes the case

The largest capsule omega-3 analysis came out in 2020. The Cochrane review "Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease" pooled 86 RCTs and over 162,000 participants.

Key numbers: – All-cause mortality: no clinically meaningful effect (RR 0.97, 95 % CI 0.93–1.01) – Cardiovascular mortality: weak, clinically trivial effect (RR 0.92) – Myocardial infarction rate: no effect – Stroke rate: no effect

The authors state explicitly: the effect of capsule omega-3 on cardiovascular outcomes in the general population is clinically negligible. This is not one contradictory trial – it is a pool of 162,000 consistently showing zero.

VITAL (NEJM 2019) followed: 25,871 healthy adults over 50, omega-3 1 g daily for 5 years, no reduction in cardiovascular events, cancer, or all-cause mortality. Based on VITAL and Cochrane 2020, ESC 2021 removed omega-3 from primary CVD prevention recommendations.

OMEMI (Circulation 2021) tested 1,014 older post-MI patients on omega-3 1.8 g daily vs placebo for 2 years: no MACE effect, atrial fibrillation rose from 3.1 % to 7.2 %.

The consolidated 2026 conclusion from international cardiology societies: fish oil capsules are useless for general-population cardiovascular risk reduction.

JELIS: the Japanese exception

One large positive trial stands out. JELIS (Japan EPA Lipid Intervention Study), Lancet 2007: 18,645 Japanese hypercholesterolaemic patients, randomised to "statin + EPA 1.8 g daily" vs statin alone. Median follow-up 4.6 years. Result: 19 % reduction in major coronary events.

Why this result did not transfer to Western populations? Three reasons.

Diet. Japanese people eat, on average, 8 times more fish than Americans or Europeans. Baseline EPA and DHA levels in JELIS participants were levels Western RCT participants never reach, even on supplements. JELIS added high-dose therapy on top of an already high "physiological baseline"; Western trials add a capsule to deficiency.

Molecule form. JELIS used pure EPA without DHA. Most Western trials (VITAL, OMEMI, STRENGTH) used EPA+DHA mixtures. The biological effects differ, and opinions on which is "the right one" for the heart diverge.

Open-label design. JELIS was not blinded: patients and doctors knew the groups. In cardiology trials this weakens confidence in subjective endpoints, though it is less critical for mortality.

The main takeaway for Russian or European patients: JELIS does not apply directly. The reproduction conditions – high dietary fish intake – are achievable through diet, not through supplements.

REDUCE-IT vs STRENGTH: a plot twist about the placebo

In 2019, REDUCE-IT (NEJM) tested icosapent ethyl (pure EPA) 4 g daily in 8,179 high-CV-risk patients with triglycerides 150–500 mg/dL on statins. Result: 25 % reduction in major events. The FDA approved Vascepa for this indication.

In 2020, STRENGTH (JAMA) used the same design but a different omega formulation (EPA+DHA mix) and a different placebo. 13,078 patients. Result: no benefit.

Why did one work and the other not? The main hypothesis: the placebo difference. REDUCE-IT used mineral oil as placebo; STRENGTH used corn oil. A later post-hoc analysis showed the mineral oil in REDUCE-IT increased inflammatory markers (CRP) and LDL in the placebo group. If the "placebo" was actively worsening outcomes, the relative benefit of icosapent ethyl may have been an illusion.

The debate continues. ESC 2021 cautiously included icosapent ethyl in recommendations for a narrow patient group while noting REDUCE-IT's limitations. EPA+DHA mixtures are not recommended for cardiovascular risk reduction.

The conclusion: even in the subgroup with real clinical benefit (severe hypertriglyceridaemia + statins + CV risk), it is about a specific molecule (icosapent ethyl), not "fish oil in general".

The side effect not printed on the label: atrial fibrillation

Supplement marketing describes omega-3 as "safe, no side effects". This is false. High-dose omega-3 therapy (2–4 g daily) dose-dependently increases atrial fibrillation risk.

Numbers from major RCTs: – REDUCE-IT: 3.1 % vs 2.1 % on placebo (p = 0.004, 38 % relative increase) – STRENGTH: 2.2 % vs 1.3 % (p = 0.003) – OMEMI: rise from 3.1 % to 7.2 % (p = 0.002)

Meta-analysis of 5 large RCTs (Lombardi et al., Circulation 2021): dose-dependent atrial fibrillation risk, clinically significant at doses of 1 g daily and above.

Physiologically the mechanism is plausible: omega-3 alters cardiomyocyte membrane electrical properties and affects atrial repolarisation. One clarification: omega-3 does not prolong the QT interval. There is no QT signal in the omega-3 literature. The specific danger is atrial fibrillation.

Practical implication. In a patient over 60 with hypertension, structural heart disease, or prior paroxysmal arrhythmia, high-dose omega-3 raises the risk of thromboembolic stroke through AF. Treatment decisions are made with a cardiologist, not from a supplement ad.

What to do

If no CVD history, low-to-moderate SCORE2 risk: – Aim for 2 servings of fatty fish per week. This is the AHA and ESC baseline. – Over-the-counter fish oil capsules provide no preventive benefit. You can skip them. – Small daily doses are not dangerous, but not helpful either.

If triglycerides above 5.6 mmol/L (500 mg/dL): – This is a medical indication for high-dose omega-3. Discuss with a cardiologist. – First choice: icosapent ethyl (Vascepa) or ethyl ester mixture (Omacor) 2–4 g daily. – Before starting: ECG, rhythm assessment, cardiovascular history.

If you had an MI or have established CVD on statins: – Evidence is mixed. Routine omega-3 is not in core ESC or ACC/AHA guidelines. – In a narrow subgroup with residual hypertriglyceridaemia, icosapent ethyl is considered.

If you have prior paroxysmal atrial fibrillation: – High-dose omega-3 (over 1 g daily) raises recurrence risk. Discuss with a cardiologist.

Sources used

– Cochrane 2020 "Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease" – Mozaffarian D, Rimm EB. JAMA 2006;296:1885-1899 – AHA Science Advisory. Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and CVD. Circulation 2018 – Manson JE et al. VITAL trial. NEJM 2019;380:23-32 – Kalstad AA et al. OMEMI trial. Circulation 2021;143:528-539 – Yokoyama M et al. JELIS trial. Lancet 2007;369:1090-1098 – Bhatt DL et al. REDUCE-IT trial. NEJM 2019;380:11-22 – Nicholls SJ et al. STRENGTH trial. JAMA 2020;324:2268-2280 – Lombardi M et al. Omega-3 and atrial fibrillation: meta-analysis. Circulation 2021;144:1981-1990 – ESC Guidelines on cardiovascular disease prevention in clinical practice 2021

This article does not replace a cardiology consultation. If you are on high-dose omega-3 or considering it in the context of cardiovascular disease, discuss it with your treating physician.